OPGN Key Statistics, Chart & Performance
The current stock price of OPGN is 1.96 USD. In the past month the price decreased by -34.88%. In the past year, price increased by 14.62%.
OPGN Latest News, Press Relases and Analysis
OPGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About OPGN
Company Profile
OpGen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland. The company went IPO on 2015-05-05. OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The firm distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The firm's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.
Company Info
OPGEN INC
9717 Key West Avenue, Suite 100
Rockville MARYLAND 20878 US
CEO: Oliver Schacht
Employees: 100
Phone: 13018699683
OPGEN INC / OPGN FAQ
What does OPGN do?
OpGen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland. The company went IPO on 2015-05-05. OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The firm distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The firm's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.
What is the stock price of OPGEN INC today?
The current stock price of OPGN is 1.96 USD. The price decreased by -14.78% in the last trading session.
Does OPGN stock pay dividends?
OPGN does not pay a dividend.
What is the ChartMill rating of OPGEN INC stock?
OPGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is OPGN stock listed?
OPGN stock is listed on the Nasdaq exchange.
What do analysts say about OPGEN INC (OPGN) stock?
6 analysts have analysed OPGN and the average price target is 3.06 USD. This implies a price increase of 56.12% is expected in the next year compared to the current price of 1.96.
OPGN Technical Analysis
OPGN Financial Highlights
Over the last trailing twelve months OPGN reported a non-GAAP Earnings per Share(EPS) of -28.18. The EPS increased by 79.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -897.5% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OPGN Forecast & Estimates
6 analysts have analysed OPGN and the average price target is 3.06 USD. This implies a price increase of 56.12% is expected in the next year compared to the current price of 1.96.
For the next year, analysts expect an EPS growth of 99.72% and a revenue growth -0.26% for OPGN